MannKind Corporation  

(Public, NASDAQ:MNKD)   Watch this stock  
Find more results for MNKD
4.11
+0.15 (3.79%)
Oct 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.87 - 4.45
52 week 0.67 - 6.96
Open 3.93
Vol / Avg. 11.43M/12.43M
Mkt cap 472.13M
P/E 3.04
Div/yield     -
EPS 1.35
Shares 114.87M
Beta 3.16
Inst. own 15%
Oct 2, 2017
MannKind Corporation - Special Call - Webcast
Sep 25, 2017
MannKind Corp at Cantor Fitzgerald Global Healthcare Conference
Sep 11, 2017
MannKind Corp at Rodman & Renshaw Global Investment Conference
Aug 7, 2017
Q2 2017 MannKind Corp Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -1633.80% 71.91%
Operating margin -1497.97% 79.70%
EBITD margin - 38.33%
Return on average assets -172.27% 107.65%
Return on average equity - -
Employees 153 -
CDP Score - -

Address

30930 Russell Ranch Rd Ste 301
WESTLAKE VILLAGE, CA 91362-7378
United States - Map
+1-818-6615000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Officers and directors

Kent Kresa Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
Michael E. Castagna Pharm.D. Chief Executive Officer, Director
Age: 40
Bio & Compensation  - Reuters
Rosabel R. Alinaya Acting Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Age: 56
Bio & Compensation  - Reuters
Steven B Binder Chief Financial Officer, Principal Accounting Officer
Age: 54
Bio & Compensation  - Reuters
Linda Adreveno Senior Vice President - Human Resources
Age: 60
Bio & Compensation  - Reuters
Joseph Kocinsky Chief Technology Officer, Corporate Vice President
Age: 52
Bio & Compensation  - Reuters
David B. Thomson Ph.D., J.D. Corporate Vice President, General Counsel, Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
Patrick McCauley J.D. Chief Commercial Officer
Bio & Compensation  - Reuters
Stuart A. Tross Ph.D. Chief People Officer
Age: 49
Bio & Compensation  - Reuters
James Samuel Shannon M.D. Director
Age: 60
Bio & Compensation  - Reuters